Soligenix Inc. (SNGX)
SNGX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2024-12-31, https://www.sec.gov/Archives/edgar/data/812796/000110465926037701/0001104659-26-037701-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2024-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | SNGX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000812796 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2024
| Line | Value |
|---|---|
| Revenue | $119K |
| Net income | -$8.3M |
| Operating income | -$9.4M |
| Net margin | -6925.1% |
| Operating margin | -7907.7% |
| Revenue growth | -85.8% |
| Cash | $7.8M |
| Total assets | $9.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 56.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "To mitigate the conditions that raise substantial doubt about the Company's ability to continue as a going concern, the Company's plans include securing: additional capital, potentially through a combination of public or private equity offerings and strategic transactions, including potential alliances and drug product collaborations; additional proceeds from government contract and grant programs; and additional pro" | 10-Q 2026-11-06 |
| Cash and burn | $9.0M cash; operating cash flow -$2.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 23,368,754 (2026-10-30); 10,086,130 a year earlier; 10,378,238 three years earlier. 3y figure adjusted for splits (1-for-16 overall). | Cover page 2026-10-30 |
| Reverse splits, 3 years | 1; latest 1-for-16 on 2024-06-06 | Source 2024-06-06 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 3 424B5 takedowns, 1 at the market | Latest 2026-01-23 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-06-12 |
| Auditor | Cherry Bekaert LLP, Tampa, Florida, United States | PCAOB Form AP 2026-04-01 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $20K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$1.1M | -$1.4M | $9.0M | No debt tags | Needs four quarters | 10-Q 2026-11-06 |
| Q2 2026 2026-06-30 | Not filed | -$2.0M | -$1.7M | $9.8M | No debt tags | Needs four quarters | 10-Q 2026-08-07 |
| Q1 2026 2026-03-31 | Not filed | -$2.8M | -$2.4M | $6.0M | No debt tags | Needs four quarters | 10-Q 2026-05-08 |
| Q4 2025 2025-12-31 | Not filed | -$2.9M | -$2.7M | $7.9M | No debt tags | Needs four quarters | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | Not filed | -$2.5M | -$2.9M | $10.5M | No debt tags | Needs four quarters | 10-Q 2026-11-06 |
| Q2 2025 2025-06-30 | Not filed | -$2.7M | -$2.7M | $5.1M | No debt tags | Needs four quarters | 10-Q 2026-08-07 |
| Q1 2025 2025-03-31 | Not filed | -$3.0M | -$1.8M | $7.3M | No debt tags | Needs four quarters | 10-Q 2026-05-08 |
| Q4 2024 2024-12-31 | $0 | -$3.0M | -$2.2M | $7.8M | $0 | $119K | 10-K 2026-03-31 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-11-06 |
| Latest annual report | 10-K | 2026-03-31 |
| Latest quarterly / interim | 10-Q | 2026-11-06 |
| Latest current report | 8-K | 2026-09-21 |
| Latest proxy | DEFA14A | 2026-08-03 |
Source: SEC EDGAR submissions feed, 1,006 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -5.9% |
| 1 month | -3.0% |
| 3 months | -15.8% |
| Year to date | -76.1% |
| 1 year | -76.8% |
| From 52-week high | -80.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TCRT | Alaunos Therapeutics Inc. | $1.60 | -1.84% | $6.7M |
| TPST | Tempest Therapeutics Inc. | $0.3418 | -10.50% | $6.8M |
| ADXN | Addex Therapeutics Ltd | $3.83 | -5.67% | $6.5M |
| XCUR | Exicure Inc. | $1.07 | -0.93% | $7.0M |
| ENVB | Enveric Biosciences Inc. | $1.44 | -4.95% | $6.4M |
| TOVX | Theriva Biologics Inc. | $0.1400 | -2.85% | $6.4M |
| LGVN | Longeveron Inc. | $2.14 | -14.06% | $7.2M |
| IMRN | Immuron Limited | $0.8996 | +2.23% | $7.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier